|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | 0.00% |
|
0.00% | -40.00% |
| Market Cap | 918K 652K 573K 532K 490K 62.94M 936K 6.36M 2.48M 30.83M 2.45M 2.4M 107M | P/E 2024 |
-40.5x | P/E 2025 | -5.33x |
|---|---|---|---|---|---|
| Enterprise Value | 1.92M 1.36M 1.2M 1.11M 1.02M 131M 1.95M 13.28M 5.18M 64.37M 5.11M 5M 223M | EV / Sales 2024 |
929,496,174x | EV / Sales 2025 | - |
| Free-Float |
53.08% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -25.00% | ||
| 6 months | -40.00% | ||
| Current year | -40.00% |
| 1 month | 0.02 | 0.02 | |
| Current year | 0.02 | 0.02 | |
| 1 year | 0.02 | 0.04 | |
| 3 years | 0.02 | 0.09 | |
| 5 years | 0.02 | 0.2 | |
| 10 years | 0.01 | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
CEO | Chief Executive Officer | 57 | 2018-08-02 |
Mahmoud Aziz
PSD | President | - | 2021-05-20 |
Danny Wayne Lee
DFI | Director of Finance/CFO | - | 2020-12-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
BRD | Director/Board Member | 57 | 2018-08-02 |
Jamie Lewin
BRD | Director/Board Member | 76 | 2019-03-10 |
Kevin Bottomley
BRD | Director/Board Member | 44 | 2019-09-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 9/9/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% | ||
| 9/9/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% | ||
| 9/9/25 | Other | Chairman | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | -50.00% | -75.00% | 652K | ||
| +0.57% | +0.13% | +16.45% | +78.10% | 48.31B | ||
| -0.50% | -0.41% | +67.13% | +107.90% | 35.33B | ||
| -1.56% | -3.13% | -4.88% | +32.80% | 11.85B | ||
| -1.11% | -3.73% | +16.41% | +81.64% | 11.64B | ||
| -0.37% | -0.19% | +36.48% | +136.73% | 8.99B | ||
| -0.27% | +0.42% | +51.66% | -6.22% | 6.93B | ||
| -0.77% | -3.00% | +13.55% | +32.01% | 6.72B | ||
| +0.24% | -4.02% | +2.19% | +192.78% | 6.43B | ||
| +1.60% | -9.55% | -30.77% | +8.47% | 5.66B | ||
| Average | -0.22% | -1.56% | +11.82% | +58.92% | 14.19B | |
| Weighted average by Cap. | -0.15% | -0.93% | +27.60% | +81.86% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.47 | - |
| Net income | -73.2K -51.93K -45.68K -42.44K -39.04K -5.02M -74.6K -507K -198K -2.46M -195K -191K -8.51M | -335K -238K -209K -194K -179K -22.96M -341K -2.32M -904K -11.25M -893K -874K -38.97M |
| Net Debt | 804K 571K 502K 466K 429K 55.11M 820K 5.57M 2.17M 26.99M 2.14M 2.1M 93.54M | 999K 709K 624K 579K 533K 68.48M 1.02M 6.92M 2.7M 33.54M 2.66M 2.61M 116M |
Employees
4,000
Sector
Pharmaceuticals
- Stock Market
- Stocks
- GENX Stock
Select your edition
All financial news and data tailored to specific country editions
















